The high-fat diet-fed mouse: A model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes

Diabetes

Volumn 53, Issue SUPPL. 3, 2004, Pages

  Winzell, Maria Sörhede ^a   Ahrén, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[(3 HYDROXY 1 ADAMANTYL)AMINO]ACETYL] 2 CYANOPYRROLIDINE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRINKING WATER; GLUCOSE; INSULIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BODY WEIGHT; CALORIC INTAKE; CONFERENCE PAPER; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; GLUCOSE BLOOD LEVEL; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESPONSE; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID DIET; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DISEASE MODELS, ANIMAL; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; MICE; MICE, INBRED C57BL; PROTEASE INHIBITORS;

EID: 3543009434     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.suppl_3.S215     Document Type: Conference Paper

References (25)

1. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49): UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 281:2005-2012, 1999
2. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3-19, 2003
3. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540-543, 1995
4. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP: Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84:491-495, 1996
5. Crouse JA, Elliott GE, Burgess TL, Chiu L, Bennett L, Moore J, Nicolson M, Pacifici RE: Altered cell surface expression and signaling of leptin receptors containing the fatty mutation. J Biol Chem 273:18365-18373, 1998
6. Rossini AA, Like AA, Dulin WE, Cahill GF Jr: Pancreatic beta cell toxicity by streptozotocin anomers. Diabetes 26:1120-1124, 1977
7. Ahren B, Sundkvist G, Mulder H, Sundler F: Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse. Diabetologia 39:383-390, 1996
8. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN: Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37:1163-1167, 1988
9. Ahren B, Pacini G: Insufficient islet compensation to insulin resistance vs reduced glucose effectiveness in glucose-intolerant mice. Am J Physiol Endocrinol Metab 283:E738-E744, 2002
10. Ahrén B, Simonsson E, Scheurink AJ, Mulder H, Myrsen U, Sundler F: Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 46:97-106, 1997
11. Sörhede Winzell M, Holm C, Ahren B: Downregulation of islet hormone-sensitive lipase during long-term high-fat feeding. Biochem Biophys Res Commun 304:273-278, 2003
12. Prpic V, Watson PM, Frampton IC, Sabol MA, Jezek GE, Gettys TW: Differential mechanisms and development of leptin resistance in A/J versus C57BL/6J mice during diet-induced obesity. Endocrinology 144:1155-1163, 2003
13. Reimer MK, Holst JJ, Ahrén B: Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146:717-727, 2002
14. Ahrén B, Sauerberg P, Thomsen C: Increased insulin secretion and normalization of glucose tolerance by cholinergic agonism in high fat-fed mice. Am J Physiol 277:E93-E102, 1999
15. Ahrén B, Holst JJ, Martensson H, Balkan B: Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 404:239-245, 2000
16. Ahren B, Holst JJ, Yu S: 1,5-Anhydro-D-fructose increases glucose tolerance by increasing glucagon-like peptide-1 and insulin in mice. Eur J Pharmacol 397:219-225, 2000
17. Ahrén B: Gut peptides and type 2 diabetes mellitus treatment. Curr Diabetes Rep 3:365-372, 2003
18. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331, 1999
19. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE: 1-[[(3-hydroxy-1-adamantyl)amino-]acetyl]-2- cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46:2774-2789, 2003
20. Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, Opara EC, Kuhn CM, Rebuffe-Scrive M: Differential effects, of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 44:645-651, 1990
21. West DB, Boozer CN, Moody DL, Atkinson RL: Dietary obesity in nine inbred mouse strains. Am J Physiol 262:R1025-R1032, 1992
22. Ahrén B, Scheurink AJW: Marked hyperleptinemia after high-fat diet associated with severe glucose intolerance in mice. Eur J Endocrinol 139:461-467, 1998
23. Parekh PI, Petro AE, Tiller JM, Feinglos MN, Surwit RS: Reversal of diet-induced obesity and diabetes in C57BL/6J mice. Metabolism 47:1089-1096, 1998
24. Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Båvenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875, 2002
25. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084, 2004